July 26, 2021
European Commission Approves Rhythm’s Drug for Rare Obesity Disorders
Read More
July 26, 2021
Denali Reports Positive Interim Data from Phase 1/2 Hunter Syndrome Trial
Read More
July 22, 2021
Spark Says Ongoing Phase 1/2 Hemophilia A Gene Therapy Data Suggests Durability
Read More
July 22, 2021
FDA Approves Octapharma’s Therapy for Adult Dermatomyositis
Read More
July 21, 2021
European Commission Approves Bluebird Bio’s Gene Therapy for CALD
Read More
July 21, 2021
FDA Approves Albireo’s Bylvay as First Drug for PFIC
Read More
July 21, 2021
FDA Grants Breakthrough Therapy Designation to Genentech for Therapy to Treat Myelodysplastic Syndromes
Read More
July 19, 2021
Cytokinetics Reports Positive Results from Mid-State Trial of Hypertrophic Cardiomyopathy
Read More
July 14, 2021
FDA Grants Breakthrough Therapy Designation to Alkeus Stargardt Disease Therapy
Read More
July 13, 2021
Gene Therapy Reverses Neurological Deficiencies in AADC
Read More
July 9, 2021
FDA Places Clinical Hold on Sigilon’s Phase 1/2 Study in Hemophilia A
Read More
July 9, 2021
BlueBird Bio Resumes Marketing TDT Gene Therapy in Europe
Read More
Load More
X